Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system

References

• Argikar, U. A., Remmel, R. P. (2009). Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos 37:229–236.
   PubMed Web of Science ®Google Scholar
• Basu, N. K., Kole, L., Owens, I. S. (2003). Evidence for phosphorylation requirement for human bilirubin UDP-glucuronosyltransferase (UGT1A1) activity. Biochem Biophys Res Commun 303:98–104.
   PubMed Web of Science ®Google Scholar
• Belanger, A. S., Caron, P., Harvey, M., Zimmerman, P. A., Mehlotra, R. K., Guillemette, C. (2009). Glucuronidation of the antiretroviral drug efavirenz (EFV) by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine (AZT). Drug Metab Dispos Epub Jun 1.
   PubMed Web of Science ®Google Scholar
• Bock, K. W., Schrenk, D., Forster, A., Griese, E. U., Morike, K., Brockmeier, D., et al. (1994). The influence of environmental and genetic factors on CYP2D6, CYP1A2, and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209–218.
   PubMedGoogle Scholar
• Bock, K. W., Wiltfang, J., Blume, R., Ullrich, D., Bircher, J. (1987). Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. Eur J Clin Pharmacol 31:677–683.
   PubMed Web of Science ®Google Scholar
• Burchell, B., Coughtrie, M., Jackson, M., Harding, D., Fournel-Gigleux, S., Leakey, J., et al. (1989). Development of human liver UDP-glucuronosyltransferases. Dev Pharmacol Ther 13(2–4):70–77.
   PubMedGoogle Scholar
• Chen, G., Blevins-Primeau, A. S., Dellinger, R. W., Muscat, J. E., Lazarus, P. (2007a). Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. Cancer Res 67:9024–9029.
   PubMed Web of Science ®Google Scholar
• Chen, G., Dellinger, R. W., Gallagher, C. J., Sun, D., Lazarus, P. (2008). Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenet Genomics 18(3):181–191.
   PubMed Web of Science ®Google Scholar
• Chen, Y., Kuehl, G. E., Bigler, J., Rimorin, C. F., Schwarz, Y., Shen, D. D., et al. (2007b). UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. Pharmacogenet Genom 17:571–579.
   PubMed Web of Science ®Google Scholar
• Choonara, I. A., McKay, P., Hain, R., Rane, A. (1989). Morphine metabolism in children. Br J Clin Pharmacol 28:599–604.
   PubMed Web of Science ®Google Scholar
• Ciotti, M., Marrone, A., Potter, C., Owens, I. S. (1997). Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 7:485–495.
   PubMedGoogle Scholar
• Congiu, M., Mashford, M. L., Slavin, J. L., Desmond, P. V. (2002). UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129–134.
   PubMed Web of Science ®Google Scholar
• Coughtrie, M. W., Burchell, B., Leakey, J. E., Hume, R. (1988). The inadequacy of perinatal glucuronidation: immunoblot analysis of the developmental expression of individual UDP-glucuronosyltransferase isoenzymes in rat and human liver microsomes. Mol Pharmacol 34:729–735.
   PubMed Web of Science ®Google Scholar
• Court, M. H. (2004). In vitro identification of UDP-glucuronosyltransferases (UGTs) involved in drug metabolism. In: Yan, Z., Caldwell, G. W. (Eds.), Optimization in drug discovery: in vitro methods (pp. 185–202 ). Totowa: Humana Press.
   Google Scholar
• Court, M. H. (2005). Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Meth Enzymol 400:104–116.
   PubMed Web of Science ®Google Scholar
• Court, M. H., Duan, S. X., Guillemette, C., Journault, K., Krishnaswamy, S., von Moltke, L. L., et al. (2002). Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 30:1257–1265.
   PubMed Web of Science ®Google Scholar
• Court, M. H., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Patten, C. J., Miners, J. O., et al. (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998–1006.
   PubMed Web of Science ®Google Scholar
• Court, M. H., Hao, Q., Krishnaswamy, S., Bekaii-Saab, T., Al-Rohaimi, A., Von Moltke, L. L., et al. (2004). UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310:656–665.
   PubMed Web of Science ®Google Scholar
• Court, M. H., Hazarika, S., Krishnaswamy, S., Finel, M., Williams, J. A. (2008). Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction. Mol Pharmacol 74:744–754.
   PubMed Web of Science ®Google Scholar
• Court, M. H., Krishnaswamy, S., Hao, Q., Duan, S. X., Patten, C. J., von Moltke, L. L., et al. (2003). Evaluation of 3’-azido-3’-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125–1133.
   PubMed Web of Science ®Google Scholar
• Court, M. H., von Moltke, L. L., Shader, R. I., Greenblatt, D. J. (1997). Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 18:213–226.
   PubMed Web of Science ®Google Scholar
• de Wildt, S. N., Kearns, G. L., Leeder, J. S., van den Anker, J. N. (1999). Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 36:439–452.
   PubMed Web of Science ®Google Scholar
• Dragacci, S., Hamar-Hansen, C., Fournel-Gigleux, S., Lafaurie, C., Magdalou, J., Siest, G. (1987). Comparative study of clofibric acid and bilirubin glucuronidation in human liver microsomes. Biochem Pharmacol 36:3923–3927.
   PubMed Web of Science ®Google Scholar
• Duguay, Y., Baar, C., Skorpen, F., Guillemette, C. (2004). A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 75:223–233.
   PubMed Web of Science ®Google Scholar
• Ehmer, U., Vogel, A., Schutte, J. K., Krone, B., Manns, M. P., Strassburg, C. P. (2004). Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39:970–977.
   PubMed Web of Science ®Google Scholar
• Ernstgard, L., Johanson, G., Karlsson, A. S., Warholm, M. (2007). Phenotyping of cytochrome P450 2E1 in vitro and in vivo. Curr Drug Metab 8:493–498.
   PubMed Web of Science ®Google Scholar
• Fleischmann, R., Remmer, H., Starz, U. (1986). Induction of cytochrome P-448 iso-enzymes and related glucuronyltransferases in the human liver by cigarette smoking. Eur J Clin Pharmacol 30:475–480.
   PubMed Web of Science ®Google Scholar
• Girard, H., Court, M. H., Bernard, O., Fortier, L. C., Villeneuve, L., Hao, Q., et al. (2004). Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14:501–515.
   PubMedGoogle Scholar
• Girard, H., Thibaudeau, J., Court, M. H., Fortier, L. C., Villeneuve, L., Caron, P., et al. (2005). UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology 42:448–457.
   PubMed Web of Science ®Google Scholar
• Girard, H., Villeneuve, L., Court, M. H., Fortier, L. C., Caron, P., Hao, Q., et al. (2006). The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos 34:1220–1228.
   PubMed Web of Science ®Google Scholar
• Girre, C., Hispard, E., Palombo, S., N’Guyen, C., Dally, S. (1993). Increased metabolism of acetaminophen in chronically alcoholic patients. Alcohol Clin Exp Res 17:170–173.
   PubMed Web of Science ®Google Scholar
• Greenblatt, D. J., Divoll, M., Harmatz, J. S., Shader, R. I. (1980). Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther 215:86–91.
   PubMed Web of Science ®Google Scholar
• Greenblatt, D. J., Harmatz, J. S., Shader, R. I. (1991). Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). Clin Pharmacokinet 21:165–177.
   PubMed Web of Science ®Google Scholar
• Greenblatt, D. J., von Moltke, L. L. (2008). Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 48:1350–1355.
   PubMed Web of Science ®Google Scholar
• He, P., Court, M. H., Greenblatt, D. J., Von Moltke, L. L. (2005). Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373–387.
   PubMed Web of Science ®Google Scholar
• Hesse, L. M., He, P., Krishnaswamy, S., Hao, Q., Hogan, K., von Moltke, L. L., et al. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225–238.
   PubMedGoogle Scholar
• Hines, R. N. (2008). The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118:250–267.
   PubMed Web of Science ®Google Scholar
• Holthe, M., Rakvag, T. N., Klepstad, P., Idle, J. R., Kaasa, S., Krokan, H. E., et al. (2003). Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenom J 3:17–26.
   PubMed Web of Science ®Google Scholar
• Huang, W., Zhang, J., Chua, S. S., Qatanani, M., Han, Y., Granata, R., et al. (2003). Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci U S A 100:4156–4161.
   PubMed Web of Science ®Google Scholar
• Innocenti, F., Liu, W., Fackenthal, D., Ramirez, J., Chen, P., Ye, X., et al. (2008). Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genom 18:683–697.
   PubMed Web of Science ®Google Scholar
• Kardon, T., Coffey, M. J., Banhegyi, G., Conley, A. A., Burchell, B., Mandl, J., et al. (2000). Transcriptional induction of bilirubin UDP-glucuronosyltransrase by ethanol in rat liver. Alcohol 21:251–257.
   PubMed Web of Science ®Google Scholar
• Kardon, T., Mile, V., Banhegyi, G., Csala, M., Burchell, B., Mandl, J., et al. (2002). Ethanol-dependent induction of bilirubin UDP-glucuronosyl-transferase in rat liver is mediated by Kupffer cells. Life Sci 70:1205–1212.
   PubMed Web of Science ®Google Scholar
• Klotz, U. (2009). Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy, S., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Court, M. H. (2003a). Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 31:133–139.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy, S., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Sudmeier, J. L., Bachovchin, W. W., et al. (2003b). Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities, and species differences. Xenobiotica 33:169–180.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy, S., Hao, Q., Al-Rohaimi, A., Hesse, L. M., von Moltke, L. L., Greenblatt, D. J., et al. (2005a). UDP-glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5’-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ther 313:1331–1339.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy, S., Hao, Q., Al-Rohaimi, A., Hesse, L. M., von Moltke, L. L., Greenblatt, D. J., et al. (2005b). UDP-glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther 313:1340–1346.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy, S., Hao, Q., von Moltke, L. L., Greenblatt, D. J., Court, M. H. (2004). Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1a6. Drug Metab Dispos 32:862–869.
   PubMed Web of Science ®Google Scholar
• Kwara, A., Lartey, M., Boamah, I., Rezk, N. L., Oliver-Commey, J., Keny, E., et al. (2009). Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients. UGT2B7*1C is associated with faster zidovadine clearance and glucuronidation. J Clin Pharmacol 49(9):1079–1090.
   PubMed Web of Science ®Google Scholar
• Lazarus, P., Zheng, Y., Aaron Runkle, E., Muscat, J. E., Wiener, D. (2005). Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genom 15:769–778.
   PubMed Web of Science ®Google Scholar
• Leakey, J. E., Hume, R., Burchell, B. (1987). Development of multiple activities of UDP-glucuronyltransferase in human liver. Biochem J 243:859–861.
   PubMed Web of Science ®Google Scholar
• Levesque, E., Benoit-Biancamano, M. O., Delage, R., Couture, F., Guillemette, C. (2008). Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics 9:869–879.
   PubMed Web of Science ®Google Scholar
• Levesque, E., Delage, R., Benoit-Biancamano, M. O., Caron, P., Bernard, O., Couture, F., et al. (2007). The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 81:392–400.
   PubMed Web of Science ®Google Scholar
• Levesque, E., Turgeon, D., Carrier, J. S., Montminy, V., Beaulieu, M., Belanger, A. (2001). Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry 40:3869–3881.
   PubMed Web of Science ®Google Scholar
• Li, Y. Q., Prentice, D. A., Howard, M. L., Mashford, M. L., Wilson, J. S., Desmond, P. V. (2000). Alcohol upregulates UDP-glucuronosyltransferase mRNA expression in rat liver and in primary rat hepatocyte culture. Life Sci 66:575–584.
   PubMed Web of Science ®Google Scholar
• Limenta, L. M., Jirasomprasert, T., Tankanitlert, J., Svasti, S., Wilairat, P., Chantharaksri, U., et al. (2008). UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers. Br J Clin Pharmacol 65:908–916.
   PubMed Web of Science ®Google Scholar
• Macdonald, J. I., Herman, R. J., Verbeeck, R. K. (1990). Sex difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. Eur J Clin Pharmacol 38:175–179.
   PubMed Web of Science ®Google Scholar
• McCarver, D. G., Hines, R. N. (2002). The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 300:361–366.
   PubMed Web of Science ®Google Scholar
• Miners, J. O., Attwood, J., Birkett, D. J. (1983). Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 16:503–509.
   PubMed Web of Science ®Google Scholar
• Miners, J. O., Attwood, J., Birkett, D. J. (1984). Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen’s metabolic pathways. Clin Pharmacol Ther 35:480–486.
   PubMed Web of Science ®Google Scholar
• Miners, J. O., Knights, K. M., Houston, J. B., Mackenzie, P. I. (2006). In vitro–in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531–1539.
   PubMed Web of Science ®Google Scholar
• Miners, J. O., Mackenzie, P. I. (1991). Drug glucuronidation in humans. Pharmacol Ther 51:347–369.
   PubMed Web of Science ®Google Scholar
• Miyagi, S. J., Collier, A. C. (2007). Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab Dispos 35:1587–1592.
   PubMed Web of Science ®Google Scholar
• Mori, Y., Koide, A., Kobayashi, Y., Morimura, K., Kaneko, M., Fukushima, S. (2002). Effect of ethanol treatment on metabolic activation and detoxification of esophagus carcinogenic N-nitrosamines in rat liver. Mutagenesis 17:251–256.
   PubMed Web of Science ®Google Scholar
• Murry, D. J., Crom, W. R., Reddick, W. E., Bhargava, R., Evans, W. E. (1995). Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 23:1110–1116.
   PubMed Web of Science ®Google Scholar
• Nagar, S., Zalatoris, J. J., Blanchard, R. L. (2004). Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies, and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 14:487–499.
   PubMedGoogle Scholar
• Nakamura, A., Nakajima, M., Yamanaka, H., Fujiwara, R., Yokoi, T. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461–1464.
   PubMed Web of Science ®Google Scholar
• Narayan, S. S., Hayton, W. L., Yost, G. S. (1991). Chronic ethanol consumption causes increased glucuronidation of morphine in rabbits. Xenobiotica 21:515–524.
   PubMed Web of Science ®Google Scholar
• Nishimura, M., Naito, S. (2006). Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21:357–374.
   PubMed Web of Science ®Google Scholar
• Nozawa, M., Ohnuma, T., Matsubara, Y., Sakai, Y., Hatano, T., Hanzawa, R., et al. (2008). The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 30:35–40.
   PubMed Web of Science ®Google Scholar
• Ochs, H. R., Greenblatt, D. J., Knuchel, M. (1985). Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. Chest 87:223–226.
   PubMed Web of Science ®Google Scholar
• Ochs, H. R., Greenblatt, D. J., Otten, H. (1981). Disposition of oxazepam in relation to age, sex, and cigarette smoking. Klin Wochenschr 59:899–903.
   PubMedGoogle Scholar
• Ohno, S., Nakajin, S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32–40.
   PubMed Web of Science ®Google Scholar
• Pacifici, G. M., Rane, A. (1982). Distribution of UDP-glucuronyltransferase in different human foetal tissues. Br J Clin Pharmacol 13:732–735.
   PubMed Web of Science ®Google Scholar
• Pacifici, G. M., Sawe, J., Kager, L., Rane, A. (1982). Morphine glucuronidation in human fetal and adult liver. Eur J Clin Pharmacol 22:553–558.
   PubMed Web of Science ®Google Scholar
• Parkinson, A., Mudra, D. R., Johnson, C., Dwyer, A., Carroll, K. M. (2004). The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193–209.
   PubMed Web of Science ®Google Scholar
• Peterkin, V. C., Bauman, J. N., Goosen, T. C., Menning, L., Man, M. Z., Paulauskis, J. D., et al. (2007). Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol 64:458–468.
   PubMed Web of Science ®Google Scholar
• Pillot, T., Ouzzine, M., Fournel-Gigleux, S., Lafaurie, C., Radominska, A., Burchell, B., et al. (1993). Glucuronidation of hyodeoxycholic acid in human liver. Evidence for a selective role of UDP-glucuronosyltransferase 2B4. J Biol Chem 268:25636–25642.
   PubMed Web of Science ®Google Scholar
• Ramchandani, R. P., Wang, Y., Booth, B. P., Ibrahim, A., Johnson, J. R., Rahman, A., et al. (2007). The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 47:78–86.
   PubMed Web of Science ®Google Scholar
• Ramirez, J., Liu, W., Mirkov, S., Desai, A. A., Chen, P., Das, S., et al. (2007). Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos 35:2149–2153.
   PubMed Web of Science ®Google Scholar
• Rane, A., Sjoqvist, F., Orrenius, S. (1973). Drugs and fetal metabolism. Clin Pharmacol Ther 14:666–672.
   PubMed Web of Science ®Google Scholar
• Rollins, D. E., von Bahr, C., Glaumann, H., Moldeus, P., Rane, A. (1979). Acetaminophen: potentially toxic metabolite formed by human fetal and adult liver microsomes and isolated fetal liver cells. Science 205:1414–1416.
   PubMed Web of Science ®Google Scholar
• Scavone, J. M., Greenblatt, D. J., LeDuc, B. W., Blyden, G. T., Luna, B. G., Harmatz, J. S. (1990). Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. Pharmacology 40:77–84.
   PubMed Web of Science ®Google Scholar
• Strassburg, C. P., Strassburg, A., Kneip, S., Barut, A., Tukey, R. H., Rodeck, B., et al. (2002). Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50:259–265.
   PubMed Web of Science ®Google Scholar
• Tankanitlert, J., Morales, N. P., Howard, T. A., Fucharoen, P., Ware, R. E., Fucharoen, S., et al. (2007). Effects of combined UDP-glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on paracetamol pharmacokinetics in beta-thalassemia/HbE. Pharmacology 79:97–103.
   PubMed Web of Science ®Google Scholar
• Turgeon, D., Carrier, J. S., Levesque, E., Hum, D. W., Belanger, A. (2001). Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778–787.
   PubMed Web of Science ®Google Scholar
• van Oijen, M. G., Barthelemy, C., Janssen, M. J., Joiris, E., Peters, W. H., Laheij, R. J., et al. (2009). Effect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers. Pharmacology 83:237–242.
   PubMed Web of Science ®Google Scholar
• Villeneuve, J. P., Raymond, G., Bruneau, J., Colpron, L., Pomier-Layrargues, G. (1983). [Pharmacokinetics and metabolism of acetaminophen in normal, alcoholic and cirrhotic subjects]. Gastroenterol Clin Biol 7:898–902.
   PubMedGoogle Scholar
• Waxman, D. J., Holloway, M. G. (2009). Centennial perspective: sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol Epub May 29.
   PubMedGoogle Scholar
• Wiener, D., Fang, J. L., Dossett, N., Lazarus, P. (2004). Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res 64:1190–1196.
   PubMed Web of Science ®Google Scholar
• Yamanaka, H., Nakajima, M., Katoh, M., Hara, Y., Tachibana, O., Yamashita, J., et al. (2004). A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14:329–332.
   PubMedGoogle Scholar
• Yue, Q. Y., Svensson, J. O., Alm, C., Sjoqvist, F., Sawe, J. (1989). Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol 28:629–637.
   PubMed Web of Science ®Google Scholar
• Yue, Q. Y., Tomson, T., Sawe, J. (1994). Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 4:193–198.
   PubMedGoogle Scholar
• Zaya, M. J., Hines, R. N., Stevens, J. C. (2006). Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos 34:2097–2101.
   PubMed Web of Science ®Google Scholar